<?xml version="1.0" encoding="UTF-8" ?>
<modsCollection xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" xmlns:slims="http://senayan.diknas.go.id" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
<mods version="3.3" ID="2331">
<titleInfo>
<title>Asian Journal of Pharmaceutical Sciences Volume 18, Issue 4 2023</title>
</titleInfo>
<typeOfResource manuscript="yes" collection="yes">mixed material</typeOfResource>
<genre authority="marcgt">bibliography</genre>
<originInfo>
<place><placeTerm type="text">China</placeTerm></place>
<publisher>China Medical University</publisher>
<dateIssued>2023</dateIssued>
<issuance>monographic</issuance>
<edition>Volume 18, Issue 4 2023</edition>
</originInfo>
<language>
<languageTerm type="code">id</languageTerm>
<languageTerm type="text">Indonesia</languageTerm>
</language>
<physicalDescription>
<form authority="gmd">Jurnal</form>
<extent></extent>
</physicalDescription>
<note>a b s t r a c t
Hepatocellular carcinoma (HCC) is now a common cause of cancer death, with no obvious
change in patient survival over the past few years. Although the traditional therapeutic
modalities for HCC patients mainly involved in surgery, chemotherapy, and radiotherapy,
which have achieved admirable achievements, challenges are still existed, such as drug
resistance and toxicity. The emerging gene therapy of clustered regularly interspaced short
palindromic repeat/CRISPR-associated nuclease 9-based (CRISPR/Cas9), as an alternative
to traditional treatment methods, has attracted considerable attention for eradicating
resistant malignant tumors and regulating multiple crucial events of target gene-editing.
Recently, advances in CRISPR/Cas9-based anti-drugs are presented at the intersection of
science, such as chemistry, materials science, tumor biology, and genetics. In this review,
the principle as well as statues of CRISPR/Cas9 technique were introduced first to show
its feasibility. Additionally, the emphasis was placed on the applications of CRISPR/Cas9
technology in therapeutic HCC. Further, a broad overview of non-viral delivery systems
for the CRISPR/Cas9-based anti-drugs in HCC treatment was summarized to delineate
their design, action mechanisms, and anticancer applications. Finally, the limitations and
prospects of current studies were also discussed, and we hope to provide comprehensively
theoretical basis for the designing of anti-drugs.</note>
<subject authority=""><topic>Delivery strategy</topic></subject>
<subject authority=""><topic>Screen gene</topic></subject>
<classification></classification><identifier type="isbn"></identifier><location>
<physicalLocation>PERPUSTAKAAN SEKOLAH TINGGI ILMU KESEHATAN SAMARINDA REPOSITORY</physicalLocation>
<shelfLocator></shelfLocator>
<holdingSimple>
<copyInformation>
<numerationAndChronology type="1">JIN0115</numerationAndChronology>
<sublocation>Perpus.Akfarsam (Jurnal Farmasi Internasional)</sublocation>
<shelfLocator>615 ASI</shelfLocator>
</copyInformation>
</holdingSimple>
</location>
<slims:digitals>
<slims:digital_item id="2204" url="https://drive.google.com/file/d/1FhJlSByS98QmQWm_4kMMR1Q4vYkL3T8J/view?usp=sharing" path="/https://drive.google.com/file/d/1FhJlSByS98QmQWm_4kMMR1Q4vYkL3T8J/view?usp=sharing" mimetype="text/uri-list">Volume 18, Issue 4 2023</slims:digital_item>
</slims:digitals><recordInfo>
<recordIdentifier>2331</recordIdentifier>
<recordCreationDate encoding="w3cdtf">2026-07-10 08:01:57</recordCreationDate>
<recordChangeDate encoding="w3cdtf">2026-07-10 08:04:29</recordChangeDate>
<recordOrigin>machine generated</recordOrigin>
</recordInfo></mods></modsCollection>